https://www.selleckchem.com/pr....oducts/Aminocaproic-
The primary outcome is difference in middle cerebral artery pulsatility (Gosling's Pulsatility Index, PI) after 3 weeks of sildenafil versus placebo. Secondary outcomes including non-inferiority of sildenafil vs cilostazol in effects on PI, percentage increase in MCA blood flow velocity and BOLD-fMRI response during inhalation of 4-6% carbon dioxide. Reduction in cerebral pulsatility and increased cerebrovascular reactivity during treatment with sildenafil would indicate potential benefit to prevent progression of SVD,
Like
Comment
Share
